Huntington's Disease

Rare Disease·MeSH: Huntington Disease

Prevalence

5.0 / 100K

14 drugs in development·12 companies·4 clinical trials

Drug Pipeline by Phase

Phase 3(1)

Drug	Company
srp-1005	Sarepta Therapeutics, Inc. (SRPT)

Phase 2(3)

Phase 1(1)

Drug	Company
ALN-HTT02	ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Preclinical(5)

Drug	Company
novartis hd program	Voyager Therapeutics, Inc. (VYGR)
novartis hd program product	Voyager Therapeutics, Inc. (VYGR)
patrol platform	NeuBase Therapeutics, Inc. (NBSE)
sc379	Sana Biotechnology, Inc. (SANA)
unspecified	Passage BIO, Inc. (PASG)

Phase 1/Phase 2(2)

Drug	Company
intra-striatal raav5-mihtt	uniQure N.V. (QURE)
WVE-003	Wave Life Sciences Ltd. (WVE)

Phase 2/Phase 3(2)

Drug	Company
dalzanemdor	Sage Therapeutics, Inc. (SAGE)
sls-005	SEELOS THERAPEUTICS, INC. (SEEL)

BioSniper tracks 14 drugs in development for Huntington's Disease across 12 companies.

There are 4 clinical trials targeting Huntington's Disease tracked by BioSniper.

The estimated prevalence of Huntington's Disease is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.